The signals that were meant to be temporary become permanent noise
At the University of São Paulo, researchers have done what medicine could not do for this condition just a decade ago: they have named the molecular culprit behind a rare childhood neurological disease, tracing its devastation to a single malfunctioning protein. CONDSIAS — a disorder that strips children of coordination, invites seizures, and worsens with every common viral illness — has now yielded its genetic secret, a novel variant in the ADPRS gene identified through the careful sequencing of an 11-year-old girl's DNA. In the long human effort to transform suffering from mystery into meaning, this discovery marks a threshold — not yet a cure, but the first clear map of where to look for one.
- A rare disease that turns ordinary childhood infections into neurological crises had gone molecularly unexplained since its first description in 2018, leaving patients and clinicians without a target to fight.
- An 11-year-old girl in Brazil carries the weight of this uncertainty in her body — progressive epilepsy, lost motor coordination, and developmental delays that sharply worsen each time a virus enters her system.
- The discovery of a second, previously unknown variant in the ADPRS gene forced researchers to solve a classic genetic puzzle: was this new variant a cause or merely a coincidence found alongside the known culprit?
- The answer revealed a precise molecular failure — the ARH3 protein, which normally erases temporary chemical distress signals in cells, is dysfunctional, allowing those signals to accumulate and silently destroy neuronal function.
- Published in Neurology Genetics and supported by the São Paulo Research Foundation, the finding now points toward targeted therapies and may surface other undiagnosed patients carrying similar variants worldwide.
A research team at the University of São Paulo has achieved the first molecular explanation for CONDSIAS, a rare and cruel childhood neurological disorder that had remained genetically obscure since it was first described in 2018. Only one prior case had ever been documented in South America. The disease brings epilepsy, progressive loss of motor coordination, and developmental delays — but its most distinctive and devastating feature is what happens when a child with CONDSIAS contracts a common viral illness. Influenza, herpes, COVID-19: any of these can trigger a sharp acceleration of the disease, as the body's own immune stress becomes a catalyst for neurological decline.
The breakthrough came through the case of an 11-year-old girl whose DNA, when sequenced, revealed two variants in the ADPRS gene on chromosome 1. One was already linked to the disease. The other was entirely new to science. The central challenge — one familiar to genetic medicine — was determining whether this novel variant was truly responsible for her symptoms or simply an incidental finding among the many rare variations any genome contains. Study coordinator Nicolas Carlos Hoch, a biochemistry professor at USP's Institute of Chemistry, described this as the essential detective work of modern genetics.
The team succeeded in making the connection by tracing the molecular mechanism involved. The ADPRS gene produces a protein called ARH3, which functions as a cellular eraser, clearing temporary chemical signals — specifically ADP-ribosylation marks — that cells use to flag internal stress like DNA damage. When ARH3 is absent or impaired, those signals never disappear. They accumulate, flooding neurons with persistent noise that disrupts the precise electrochemical processes the brain depends on. What was meant to be a transient alarm becomes a permanent malfunction.
Hoch noted that this kind of discovery was simply impossible in earlier decades, when clinicians could observe and compare symptoms but lacked the sequencing tools to reach the molecular level. The finding, published in Neurology Genetics with support from the São Paulo Research Foundation, does more than explain one child's illness. It identifies a therapeutic target, suggests strategies for intervention in the disease's molecular cascade, and may help locate other patients around the world who carry similar variants and remain undiagnosed. For a condition defined until now only by its symptoms and its relentless progression, a molecular target is where hope begins.
A team of researchers at the University of São Paulo has identified a genetic variant that explains a rare and devastating childhood neurological disorder, offering the first molecular clarity on a condition that had remained largely mysterious since its initial description less than a decade ago.
The disease is called CONDSIAS—a clinical acronym for stress-induced childhood neurodegeneration with ataxia and seizures. It was first documented in 2018, and until now, only a single case had been reported anywhere in South America. The condition announces itself through a constellation of neurological failures: epilepsy, progressive loss of motor coordination, developmental delays, and a steady deterioration of the nervous system. But what makes CONDSIAS particularly cruel is its relationship to infection. When a child with this disease contracts a common viral illness—influenza, herpes, or COVID-19—the condition does not simply persist. It worsens dramatically. The body's natural immune response, the physiological stress that accompanies fighting off infection, becomes a trigger that accelerates the disease's progression.
The USP team's breakthrough centered on an 11-year-old girl who carried the clinical hallmarks of CONDSIAS. When researchers sequenced her DNA, they found two variants in the ADPRS gene, located on chromosome 1. One variant was already known to cause the disease. The other was entirely new to science, its clinical significance unknown. The central puzzle was determining whether this novel variant actually contributed to her illness or was simply a coincidental finding—a common problem in genetic medicine, where patients' genomes routinely contain multiple rare variations, and distinguishing the culprits from the bystanders requires careful detective work.
Nicolas Carlos Hoch, a biochemistry professor at the University of São Paulo's Institute of Chemistry and the study's coordinator, explained the methodological challenge: when you examine a patient's DNA, discovering multiple rare variants is routine. The difficult question is whether any given variant actually explains the patient's symptoms. The research, published in the journal Neurology Genetics with support from the São Paulo Research Foundation, succeeded in making that connection.
The team's investigation revealed the molecular mechanism at work. The ADPRS gene encodes a protein called ARH3, which functions as a kind of molecular eraser inside cells. Its job is to remove a chemical modification called ADP-ribosylation—a temporary signal that cells use to flag problems, such as DNA damage. When ARH3 is absent or dysfunctional, these warning signals are never cleared. They accumulate inside the cell, like unread messages piling up in an inbox. For neurons, which are exquisitely sensitive to molecular imbalances, this accumulation is catastrophic. The signals that were meant to be temporary become permanent noise, disrupting the delicate electrochemical processes that allow the brain and nervous system to function.
Hoch also noted how technological progress made this discovery possible. In earlier decades, clinicians could describe symptoms and compare patients with similar presentations, but they lacked the tools to identify the underlying genetic cause. Modern DNA sequencing has changed that calculus entirely, making it feasible to move from clinical observation to molecular diagnosis.
The discovery does more than explain a single girl's illness. It opens a pathway toward understanding other patients who may carry similar genetic variants, and it suggests potential therapeutic strategies—ways to intervene in the molecular cascade that leads to neurodegeneration. For a disease that had been defined only by its symptoms and its devastating progression, having a molecular target is the beginning of hope.
Notable Quotes
When you analyze a patient's DNA, it's common to find more than one rare variant. The question is whether that variant explains the patient's symptoms or not.— Nicolas Carlos Hoch, study coordinator
In the past, you could describe symptoms and compare similar patients, but you didn't have molecular diagnosis. Now the technology makes that possible.— Nicolas Carlos Hoch
The Hearth Conversation Another angle on the story
Why does this particular disease get worse when a child catches the flu or COVID?
Because the immune response itself creates physiological stress. The body's natural alarm system, which is supposed to help fight infection, becomes a problem for these children. Their cells can't clear the warning signals properly, and infection amplifies that dysfunction.
So the genetic variant is the vulnerability, and the virus is the trigger?
Exactly. The variant means the molecular eraser doesn't work. The virus doesn't cause the disease—it just makes the existing problem catastrophically worse.
How rare is this? Could there be other children out there with the same variant who haven't been diagnosed?
Very rare. Only one case reported in all of South America until now. But that's partly because the disease is so new to medical literature. There could be others, undiagnosed. This discovery gives doctors a genetic marker to look for.
What happens next for this girl and others like her?
The immediate next step is understanding whether you can restore the function of that eraser protein, or find ways to prevent the signals from accumulating in the first place. It's early, but at least now there's a target.
Does this explain other neurological diseases?
Possibly. The ADPRS gene might be involved in other conditions we haven't connected yet. Once you understand one mechanism, you often find it operating in unexpected places.